CLINICAL TRIALS PROFILE FOR LY900014
✉ Email this page to a colleague
Clinical Trials for LY900014
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02636361 ↗ | A Study of Various Formulations of LY900014 in Healthy Participants | Completed | Eli Lilly and Company | Phase 1 | This study will evaluate how quickly the body absorbs, breaks down, and gets rid of the different formulations of LY900014. This study will determine how the different formulations, when injected under the skin, will affect the blood sugar levels in the body, and how safe it is. |
| NCT02703324 ↗ | A Study of LY900014 Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps | Completed | Eli Lilly and Company | Phase 1 | This study evaluated a blood sugar lowering insulin, LY900014, delivered by an insulin pump continuously under the skin. The study was conducted in participants with type 1 diabetes mellitus to investigate how the human body processed LY900014 and its effect on blood sugar levels when it was delivered via an insulin pump. Side effects and tolerability were be documented. |
| NCT02703337 ↗ | A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection Therapy | Completed | Eli Lilly and Company | Phase 1 | The study will be conducted in participants with type 2 diabetes on insulin injection therapy to investigate how the body processes LY900014 and the effect of LY900014 on blood sugar levels. Side effects and tolerability will be documented. The study will be conducted in two parts (Part A and Part B) to achieve its objectives. Participants are expected to enroll in both parts. |
| NCT02703350 ↗ | A Study of LY900014 in Participants With Type 1 Diabetes on Insulin Injection Therapy | Completed | Eli Lilly and Company | Phase 1 | The study will be conducted in participants with type1 diabetes on insulin injection therapy to investigate how the body processes LY900014 and the effect of LY900014 on blood sugar levels. Side effects and tolerability will be documented. The study will be conducted in two parts (Part A and Part B) to achieve its objectives. Participants are expected to enroll in both parts. |
| NCT02752087 ↗ | A Study to Compare the Effects of a Test and Reference Formulation of LY900014 in Healthy Participants | Completed | Eli Lilly and Company | Phase 1 | This study of healthy participants evaluated the concentration of a test LY900014 and a reference LY900014 formulation in the bloodstream and how it affected the blood sugar levels. The whole study, including screening, took up to 8 weeks to complete. |
| NCT02770521 ↗ | A Study of Treprostinil and a New Formulation of LY900014 in Healthy Japanese Participants | Completed | Eli Lilly and Company | Phase 1 | The aims of this study are to evaluate: - The safety and tolerability of a single dose of treprostinil given subcutaneously (as an injection just under the skin) - The pharmacokinetic profile (how the body absorbs, breaks down, and gets rid of) of a single subcutaneous dose of a new LY900014 formulation in healthy Japanese participants. The study has two parts. Participants may only enroll in one part. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for LY900014
Condition Name
Clinical Trial Locations for LY900014
Trials by Country
Clinical Trial Progress for LY900014
Clinical Trial Phase
Clinical Trial Sponsors for LY900014
Sponsor Name
